ASP Isotopes Inc.

ASP Isotopes Inc. is a development-stage advanced materials company dedicated to the production and commercialization of enriched isotopes for a variety of industries, including nuclear medicine, healthcare, green energy, quantum computing, and advanced semiconductors. The company utilizes proprietary technologies, primarily the Aerodynamic Separation Process (ASP) and Quantum Enrichment (QE), to enrich natural isotopes into higher concentration products. Headquartered in Dallas, Texas, ASP Isotopes Inc. operates globally with manufacturing facilities in Pretoria, South Africa, and a presence in Hong Kong and the United States.

The company's product portfolio includes a wide range of enriched isotopes such as Molybdenum-100, Carbon-14, Silicon-28, Ytterbium-176, Gadolinium-160, Uranium-235 (High-Assay Low-Enriched Uranium or HALEU), and Lithium-6. These isotopes serve critical applications in pharmaceuticals, agrochemicals, medical diagnostics, and advanced materials research. Through its subsidiary PET Labs, ASP Isotopes also provides radioisotopes for oncology treatments. A recent strategic expansion includes the acquisition of Renergen Limited, a producer of liquefied helium and natural gas, broadening its offerings into critical gases.

ASP Isotopes Inc. is publicly traded on NASDAQ under the ticker ASPI, having gone public in November 2022. Recent developments include the commencement of commercial production for Silicon-28, Carbon-14, and Ytterbium-176 at its South African facilities. The company's wholly-owned subsidiary, Quantum Leap Energy (QLE), which focuses on nuclear fuels, is slated for a spin-out as a separate public entity and established its global headquarters in Austin, Texas, in February 2026. Leadership includes Paul Mann as Chairman and CEO, and Robert Ainscow as COO. The company reported $23.85 million in revenue for 2025 and aims for over $300 million in EBITDA by 2031.